Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rapamune cyclosporine-sparing regimen approved

Executive Summary

New regimen for Wyeth's Rapamune (sirolimus) will allow patients at low to moderate immunologic risk to stop taking cyclosporine two to four months after kidney transplantation and receive higher doses of Rapamune. Clinical research to assess the safety and efficacy of cyclosporine withdrawal in high-risk patients and patients who have been taking a combination of immunosuppressive medications for more than four months is underway, an April 11 1FDA "Talk Paper" states. An FDA advisory committee voted five to four that the Rapamune cyclosporine-sparing data were not sufficient for approval (2"The Pink Sheet" Jan. 28, 2002, p. 11)...

You may also be interested in...



Wyeth Rapamune Boxed Warning On Lung Transplants Added To Labeling

Wyeth has added a boxed warning to Rapamune labeling to reflect an increased incidence of bronchial anastomotic dehiscence in de novo lung transplant patients administered the immunosuppressant

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel